Bristol-Myers Squibb Co
NYSE:BMY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bristol-Myers Squibb Co
NYSE:BMY
|
US |
|
X
|
XOMA Corp
LSE:0M26
|
US |
|
TrueBlue Inc
NYSE:TBI
|
US |
|
R
|
Robert Half International Inc
F:RHJ
|
US |
Wall St Price Targets
BMY Price Targets Summary
Bristol-Myers Squibb Co
According to Wall Street analysts, the average 1-year price target for
BMY is 63.18 USD with a low forecast of 33.43 USD and a high forecast of 78.75 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BMY's stock price target?
Price Target
63.18
USD
According to Wall Street analysts, the average 1-year price target for
BMY is 63.18 USD with a low forecast of 33.43 USD and a high forecast of 78.75 USD.
What is the Revenue forecast for Bristol-Myers Squibb Co?
Projected CAGR
-3%
Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 8 years is -3%.
What is the Gross Profit forecast for Bristol-Myers Squibb Co?
Projected CAGR
-2%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 8 years is -2%.
What is the Operating Income forecast for Bristol-Myers Squibb Co?
Projected CAGR
-2%
Over the last 13 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 8 years is -2%.
What is the Pre-Tax Income forecast for Bristol-Myers Squibb Co?
Projected CAGR
14%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 11%. The projected CAGR for the next 3 years is 14%.
What is the Net Income forecast for Bristol-Myers Squibb Co?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Net Income has been 10%. The projected CAGR for the next 8 years is 7%.